Fig. 6From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 monthsUnsupervised hierarchical clustering of protein lists obtained by analyzing lung biopsies from omalizumab responders (OR, blue) and non-omalizumab responders (NOR, red). a Before (baseline). b After 36 months of anti-IgE treatment. The clusters obtained were based on SEQUEST score value and proved to be well structured (agglomerative coefficients >0.7). OR and NOR are classified according to whether they experienced a reduction in RBM thickness (OR) or no reduction in RBM thickness (NOR) after 12 months of anti-IgE treatmentBack to article page